SRR12475148
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+0.320
- INTERFERON_ALPHA_RESPONSE+0.320
- TGF_BETA_SIGNALING+0.240
- INTERFERON_GAMMA_RESPONSE+0.230
- PROTEIN_SECRETION+0.220
- PI3K_AKT_MTOR_SIGNALING+0.190
- PANCREAS_BETA_CELLS+0.110
- ANDROGEN_RESPONSE+0.100
- COMPLEMENT+0.100
- ADIPOGENESIS+0.080
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- E2F_TARGETS-0.620
- MYC_TARGETS_V1-0.600
- G2M_CHECKPOINT-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- ANGIOGENESIS-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.400
- MTORC1_SIGNALING-0.390
- HEDGEHOG_SIGNALING-0.290
- COAGULATION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475139 | — | — | 0.847 |
| 2 | SRR12475121 | — | — | 0.843 |
| 3 | BS_5PJCHF6V | Med | Medulloblastoma | 0.807 |
| 4 | 7c025d06-2593-493c-b4a5-9f976149b0e2 | — | — | 0.797 |
| 5 | C3L-02348 | — | cohortA1 | 0.797 |
| 6 | BS_2SFTWNVE | Med | Medulloblastoma | 0.779 |
| 7 | SRR12475136 | — | — | 0.777 |
| 8 | BS_ERWT0ZWE | Med | Medulloblastoma | 0.775 |
| 9 | SRR12475115 | — | — | 0.772 |
| 10 | TCGA-55-7573-01A-11R-2039-07 | — | cohortA1 | 0.768 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 0.320 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |